LOGIN  |  REGISTER
Terns Pharmaceuticals

Spok Sets Date to Report Second Quarter 2025 Results

July 23, 2025 | Last Trade: US$13.90 0.07 0.51

PLANO, Texas / Jul 23, 2025 / Business Wire / Spok Holdings, Inc. (NASDAQ: SPOK), a global leader in healthcare communications, today announced it will release its second quarter 2025 operating results on Wednesday, July 30, 2025, after the close of the U.S. financial markets.

Management will host a conference call and webcast to discuss these financial results on Wednesday, July 30, 2025, at 5:00 p.m. ET. The presentation is open to all interested parties and may include forward-looking information.

Conference Call Details

Date/Time

 

Wednesday, July 30, 2025, at 5:00 p.m. ET

   

Webcast:

 

https://www.webcast-eqs.com/register/Spok_2Q_2025/en

   

U.S. Toll-Free Dial In:

 

877-407-0890

   

International Dial In:

 

+1-201-389-0918

To access the call, please dial in approximately ten minutes before the start of the call. For those unable to join the live call, an OnDemand version of the webcast will be available following the call under the URL link and on the investor relations website.

About Spok

Spok Holdings, Inc. (NASDAQ: SPOK), headquartered in Plano, Texas, is proud to be a global leader in healthcare communications. We deliver clinical information to care teams when and where it matters most to improve patient outcomes. Top hospitals rely on the Spok Care Connect® platform to enhance workflows for clinicians and support administrative compliance. Our customers send over 70 million messages each month through their Spok® solutions. Spok enables smarter, faster clinical communication.

Spok is a trademark of Spok Holdings, Inc. Spok Care Connect and Spok Mobile are trademarks of Spok, Inc.

Stock Quote

Last Trade: US$13.90
Daily Change: 0.07 0.51
Daily Volume: 98,708
Market Cap: US$286.340M

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page